Full text is available at the source.
Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm
Unusual Gut Bacteria, Small Intestine Overgrowth, and Fatty Liver Disease: A New Understanding
AI simplified
Abstract
The gut microbiota may play a significant role in the development of non-alcoholic fatty liver disease (NAFLD), which affects nearly 25% of the global population.
- Disturbances in the gut microbiome, such as small intestinal bacterial overgrowth (SIBO), are observed in patients with liver disease.
- Gut bacteria and their products could contribute to liver conditions like steatosis, inflammation, fibrosis, and cancer.
- Animal studies have identified mechanisms through which gut microbiota may worsen liver disease progression.
- Evidence from human studies is emerging but remains less comprehensive than animal data.
- Therapeutic approaches targeting the microbiome have been considered, though practical applications in medicine are not yet established.
AI simplified